A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

2023-506881-30-00 Protocol CGME751A12101 Human pharmacology (Phase I) - Other Ended

Start 15 May 2024 · End 6 May 2026 · Status Ended · 6 EU/EEA countries · 25 sites · Protocol CGME751A12101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 417
Countries 6
Sites 25

Melanoma

Key facts

Sponsor
H e x a l AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 May 2024 → 6 May 2026
Decision date (initial)
2024-04-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Melanoma

VersionLevelCodeTermSystem organ class
21.1 PT 10025669 Malignant melanoma stage II 100000004864
21.1 PT 10025670 Malignant melanoma stage III 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

H e x a l AG

Sponsor organisation
H e x a l AG
Address
Industriestrasse 25
City
Holzkirchen
Postcode
83607
Country
Germany

Scientific contact point

Organisation
H e x a l AG
Contact name
Biosimilar Clinical Trials Information Point

Public contact point

Organisation
H e x a l AG
Contact name
Biosimilar Clinical Trials Information Point

Locations

6 EU/EEA countries · 25 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 8 2
Germany Ended 14 3
Italy Ended 20 4
Lithuania Ended 10 2
Romania Ended 25 2
Spain Ended 59 12
Rest of world
Korea, Republic of, Mexico, South Africa, Philippines, Malaysia, Georgia, Brazil, United States, Turkey, Serbia, Bosnia and Herzegovina
281

Investigational sites

France

2 sites · Ended
Besancon University Hospital Center
Oncologie médicale, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Centre Hospitalier Universitaire De Nantes
Dermatologie, 1 Place Alexis Ricordeau, 44000, Nantes

Germany

3 sites · Ended
Fachklinik Hornheide e.V.
Oncology, Dorbaumstrasse 300, Handorf, Muenster
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Dermatology, Langenbeckstrasse 1, Oberstadt, Mainz
Eberhard Karls Universitaet Tuebingen
Dermatology, Liebermeisterstrasse 25, Innenstadt, Tuebingen

Italy

4 sites · Ended
IRCCS Istituto Nazionale Tumori Fondazione Pascale
SC Oncologia Clinica Sperimentale del Melanoma, Immunoterapia e Terapie Innovative, Via Mariano Semmola 52, 80131, Naples
Azienda Ospedaliera Universitaria Mater Domini
Centro di Sperimentazioni di Fase I in Oncologia Medica e Oncoematologia-UOC Oncologia Medica Trasla, Viale Tommaso Campanella 115, 88100, Catanzaro
Humanitas Research Hospital
Unità di Fase I - Istituto Clinico Humanitas, Via Alessandro Manzoni 56, 20089, Rozzano
Fondazione IRCCS Policlinico San Matteo
San Matteo Phase I Clinical Trial Unit and Experimental Therapy, Viale Camillo Golgi 19, 27100, Pavia

Lithuania

2 sites · Ended
Klaipedos universiteto ligonine VšĮ
2600: Chemotherapy, Liepojos G. 41, Klaipedos M. Sav., Klaipeda
Nacionalinis vezio institutas
Conservative Tumour Therapy, Santariskiu G. 1, Vilniaus M. Sav., Vilnius

Romania

2 sites · Ended
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Medical Oncology II Department, Radiotherapy I Department, Soseaua Fundeni 252, 022328, Bucharest
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Radiotherapy Department, Strada Republicii 34-36, 400015, Cluj-Napoca

Spain

12 sites · Ended
Hospital Universitario Y Politecnico La Fe
Onco-Hematologia Pediatrica, Avenida De Fernando Abril Martorell 106, 46026, Valencia
University Clinical Hospital Virgen De La Arrixaca
Oncología, Carretera De Cartagena Sn, El Palmar, Murcia
Hospital Universitario Fundacion Jimenez Diaz
Oncología Médica, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Virgen De La Macarena
Oncología Médica, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Institut Catala D'oncologia
Oncología Médica, Carretera Canyet S/n, 08916, Badalona
Fundacion Instituto Valenciano De Oncologia
Oncología, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital De La Santa Creu I Sant Pau
Oncología Médica, Carrer De San Quinti 89, 08041, Barcelona
University Hospital Virgen Del Rocio S.L.
Oncología, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital San Pedro De Alcantara
Oncología, Avenida De Pablo Naranjo Porras S/n, 10002, Caceres
Hospital Unviersitario Miguel Servet
Oncología, Paseo De Isabel La Catolica 1-3, 50009, Zaragoza
Complexo Hospitalario Universitario De Santiago
Oncología Médica, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitari Vall D Hebron
Oncología Médica, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-07-10 2026-04-24 2025-07-10 2025-11-18
Germany 2024-08-01 2026-04-21 2024-08-01 2025-11-18
Italy 2024-11-19 2025-11-20 2024-11-19 2025-11-18
Lithuania 2024-09-23 2026-04-16 2024-09-23 2025-11-18
Romania 2024-05-15 2026-05-05 2024-05-15 2025-11-18
Spain 2024-05-29 2026-04-21 2024-05-29 2025-11-18

Application history

12 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-30 Germany Acceptable
2024-04-09
2024-04-09
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-17 Acceptable 2024-05-15
3 SUBSTANTIAL MODIFICATION SM-5 2024-04-18 Germany Acceptable 2024-05-02
4 SUBSTANTIAL MODIFICATION SM-2 2024-04-22 Acceptable 2024-07-02
5 SUBSTANTIAL MODIFICATION SM-3 2024-04-22 Acceptable 2024-05-20
6 SUBSTANTIAL MODIFICATION SM-4 2024-04-22 Acceptable 2024-06-03
7 SUBSTANTIAL MODIFICATION SM-7 2024-06-04 Acceptable 2024-06-14
8 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-14 Germany Acceptable 2024-10-14
9 SUBSTANTIAL MODIFICATION SM-8 2024-11-21 Germany Acceptable
2025-02-10
2025-02-11
10 NON SUBSTANTIAL MODIFICATION NSM-2 2025-07-10 Acceptable
2025-02-10
2025-07-10
11 NON SUBSTANTIAL MODIFICATION NSM-3 2025-08-04 Germany Acceptable
2025-02-10
2025-08-04
12 SUBSTANTIAL MODIFICATION SM-9 2025-10-13 Germany Acceptable 2025-11-10